US Patent

US12521400 — Administration of benzodiazepine compositions

Formulation · Assigned to Neurelis Inc · Expires 2029-03-27 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of benzodiazepine drugs for nasal administration.

USPTO Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Drugs covered by this patent

Valium (diazepam) · Generic (originally Roche)

Patent Metadata

Patent number: US12521400
Jurisdiction: US
Classification: Formulation
Expires: 2029-03-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Neurelis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.